Valuation: Poltreg S.A.

Market Cap 13Cr 3.2Cr 2.86Cr 2.63Cr 2.39Cr 4.46Cr 303.41Cr 4.54Cr 31Cr 159.6Cr 12Cr 12Cr 503.33Cr P/E 2026 *
-3.87x
P/E 2027 * -1.4x
Enterprise Value 13Cr 3.32Cr 2.98Cr 2.74Cr 2.48Cr 4.64Cr 315.45Cr 4.72Cr 33Cr 165.94Cr 12Cr 12Cr 523.3Cr EV / Sales 2026 *
164x
EV / Sales 2027 * 231x
Free-Float
67.57%
Yield 2026 *
-
Yield 2027 * -
1 week+1.49%
Current month-4.23%
1 month-0.49%
3 months-15.00%
6 months+20.00%
Current year-16.73%
1 week 19.25
Extreme 19.25
21.3
1 month 19
Extreme 19
21.3
Current year 16
Extreme 16
28.6
1 year 16
Extreme 16
29.5
3 years 16
Extreme 16
60
5 years 16
Extreme 16
73.9
10 years 16
Extreme 16
73.9
Manager TitleAgeSince
Chief Executive Officer - 01/05/2019
Chief Tech/Sci/R&D Officer - 01/11/2021
Corporate Officer/Principal - 21/02/2024
Director TitleAgeSince
Chairman - 24/05/2021
Director/Board Member 51 21/05/2021
Director/Board Member 43 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+1.49%-20.00%-65.19% 3.2Cr
-0.62%-1.87%+42.87%+64.15% 6.38TCr
+0.35%+3.20%+14.40%+81.76% 5.64TCr
+0.53%+1.96%+16.24%+103.35% 5.46TCr
-2.81%-4.31%+23.50%+47.83% 4.41TCr
-0.33%-1.93%+19.28%+98.80% 4.21TCr
+0.55%+2.31%+225.14%+866.21% 4.1TCr
+3.27%+47.96%+112.84%+96.58% 3.49TCr
+1.22%-1.44%+14.57%+46.95% 3.28TCr
+0.89%+20.55%-40.62%+349.24% 2.47TCr
Average +0.31%+6.69%+40.82%+168.97% 3.94TCr
Weighted average by Cap. +0.18%+5.44%+47.99%+176.65%

Financials

2026 *2027 *
Net sales 8L 2L 2L 2L 2L 3L 1.93Cr 3L 19.93L 1.01Cr 8L 7L 3.2Cr 10L 3L 2L 2L 2L 4L 2.41Cr 4L 24.91L 1.27Cr 10L 9L 3.99Cr
Net income -3.1Cr -78.61L -70.4L -64.76L -58.67L -1.1Cr -75Cr -1.12Cr -7.72Cr -39Cr -2.95Cr -2.89Cr -123.82Cr -9.57Cr -2.43Cr -2.17Cr -2Cr -1.81Cr -3.39Cr -230.41Cr -3.45Cr -24Cr -121.2Cr -9.11Cr -8.91Cr -382.23Cr
Net Debt 50L 12.68L 11.35L 10.44L 9L 17.69L 12Cr 18.02L 1.25Cr 6.33Cr 47.58L 46.57L 20Cr 10Cr 2.66Cr 2.38Cr 2.19Cr 1.99Cr 3.71Cr 252.8Cr 3.78Cr 26Cr 132.98Cr 9.99Cr 9.78Cr 419.38Cr
Projected Income Statement - Annual - Poltreg S.A.
Logo Poltreg S.A.
Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.
Employees
34
Date Price Change Volume
30/26/30 PLN 21.30 +4.41% 6,025
29/26/29 PLN 20.40 -0.97% 7,073
28/26/28 PLN 20.60 -.--% 1,698
27/26/27 PLN 20.60 +2.49% 1,980
26/26/26 PLN 20.10 -.--% 1,332
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
21.30PLN
Average target price
29.30PLN
Spread / Average Target
+37.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Poltreg S.A.